Cyfuse Biomedical K.K. (TYO:4892)
Japan
· Delayed Price · Currency is JPY 645.00
+24.00 (3.86%)
Mar 10, 2026, 1:35 PM JST
Cyfuse Biomedical K.K. Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Cash & Equivalents | 3,726 | 3,052 | 3,873 | 4,437 | 2,413 | Upgrade
|
| Cash & Short-Term Investments | 3,726 | 3,052 | 3,873 | 4,437 | 2,413 | Upgrade
|
| Cash Growth | 22.08% | -21.20% | -12.71% | 83.88% | 16.46% | Upgrade
|
| Accounts Receivable | 5 | 20 | 17 | 13 | 57 | Upgrade
|
| Other Receivables | 40 | 43 | 32 | 56 | - | Upgrade
|
| Receivables | 45 | 63 | 49 | 69 | 57 | Upgrade
|
| Inventory | 88 | 55 | 46 | 40 | 61 | Upgrade
|
| Prepaid Expenses | 72 | 51 | 16 | 17 | 5 | Upgrade
|
| Other Current Assets | 3 | 19 | 3 | 2 | 22 | Upgrade
|
| Total Current Assets | 3,934 | 3,240 | 3,987 | 4,565 | 2,558 | Upgrade
|
| Property, Plant & Equipment | 155 | 141 | 169 | 189 | 27 | Upgrade
|
| Long-Term Investments | 173 | 131 | 53 | 55 | 55 | Upgrade
|
| Other Intangible Assets | 3 | 4 | 4 | 5 | 4 | Upgrade
|
| Other Long-Term Assets | 1 | 2 | 1 | 1 | 2 | Upgrade
|
| Total Assets | 4,266 | 3,518 | 4,214 | 4,815 | 2,646 | Upgrade
|
| Accounts Payable | 69 | 15 | 2 | 4 | 8 | Upgrade
|
| Accrued Expenses | 12 | 16 | 19 | 25 | 6 | Upgrade
|
| Short-Term Debt | 485 | 507 | 550 | 467 | 128 | Upgrade
|
| Current Portion of Long-Term Debt | 184 | 18 | 18 | 77 | 72 | Upgrade
|
| Current Portion of Leases | - | - | - | - | 8 | Upgrade
|
| Current Income Taxes Payable | 63 | 59 | 47 | 74 | 74 | Upgrade
|
| Current Unearned Revenue | - | 20 | 19 | 22 | 19 | Upgrade
|
| Other Current Liabilities | 53 | 13 | 11 | 13 | 71 | Upgrade
|
| Total Current Liabilities | 866 | 648 | 666 | 682 | 386 | Upgrade
|
| Long-Term Debt | 642 | 327 | 345 | 363 | 359 | Upgrade
|
| Other Long-Term Liabilities | 2 | 1 | 1 | 1 | 1 | Upgrade
|
| Total Liabilities | 1,510 | 976 | 1,012 | 1,046 | 746 | Upgrade
|
| Common Stock | 1,828 | 1,364 | 1,283 | 1,272 | 100 | Upgrade
|
| Additional Paid-In Capital | 4,450 | 3,986 | 3,905 | 3,893 | 2,721 | Upgrade
|
| Retained Earnings | -3,622 | -2,858 | -1,986 | -1,396 | -922 | Upgrade
|
| Comprehensive Income & Other | 100 | 50 | - | - | 1 | Upgrade
|
| Shareholders' Equity | 2,756 | 2,542 | 3,202 | 3,769 | 1,900 | Upgrade
|
| Total Liabilities & Equity | 4,266 | 3,518 | 4,214 | 4,815 | 2,646 | Upgrade
|
| Total Debt | 1,311 | 852 | 913 | 907 | 567 | Upgrade
|
| Net Cash (Debt) | 2,415 | 2,200 | 2,960 | 3,530 | 1,846 | Upgrade
|
| Net Cash Growth | 9.77% | -25.68% | -16.15% | 91.22% | 19.48% | Upgrade
|
| Net Cash Per Share | 274.37 | 273.27 | 378.89 | 1323.28 | 3688.31 | Upgrade
|
| Filing Date Shares Outstanding | 9.62 | 8.14 | 7.83 | 6.44 | 0.5 | Upgrade
|
| Total Common Shares Outstanding | 9.62 | 8.14 | 7.83 | 6.44 | 0.5 | Upgrade
|
| Working Capital | 3,068 | 2,592 | 3,321 | 3,883 | 2,172 | Upgrade
|
| Book Value Per Share | 286.63 | 312.31 | 409.12 | 585.09 | 3796.20 | Upgrade
|
| Tangible Book Value | 2,753 | 2,538 | 3,198 | 3,764 | 1,896 | Upgrade
|
| Tangible Book Value Per Share | 286.31 | 311.82 | 408.60 | 584.31 | 3788.21 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.